These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 31467225)

  • 1. EPB41L5 is Associated With the Metastatic Potential of Low-grade Pancreatic Neuroendocrine Tumors.
    Saller J; Seydafkan S; Shahid M; Gadara M; Cives M; Eschrich SA; Boulware D; Strosberg JR; Aejaz N; Coppola D
    Cancer Genomics Proteomics; 2019; 16(5):309-318. PubMed ID: 31467225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of membrane proteins in primary and metastatic gastrointestinal neuroendocrine tumors.
    Carr JC; Sherman SK; Wang D; Dahdaleh FS; Bellizzi AM; O'Dorisio MS; O'Dorisio TM; Howe JR
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3(0 3):S739-S746. PubMed ID: 24114056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinically Significant Differences in Ki-67 Proliferation Index Between Primary and Metastases in Resected Pancreatic Neuroendocrine Tumors.
    Richards-Taylor S; Tilley C; Jaynes E; Hu H; Armstrong T; Pearce NW; Plant R; Cave J
    Pancreas; 2017; 46(10):1354-1358. PubMed ID: 28984786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different Hormonal Expression Patterns Between Primary Pancreatic Neuroendocrine Tumors and Metastatic Sites.
    Kimura H; Ohtsuka T; Fujimoto T; Date K; Matsunaga T; Cases AI; Abe A; Mizuuchi Y; Miyasaka Y; Ito T; Oda Y; Nakamura M; Tanaka M
    Pancreas; 2016 Aug; 45(7):947-52. PubMed ID: 26684862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors.
    Scott AT; Weitz M; Breheny PJ; Ear PH; Darbro B; Brown BJ; Braun TA; Li G; Umesalma S; Kaemmer CA; Maharjan CK; Quelle DE; Bellizzi AM; Chandrasekharan C; Dillon JS; O'Dorisio TM; Howe JR
    Clin Cancer Res; 2020 Apr; 26(8):2011-2021. PubMed ID: 31937620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Function and clinical relevance of RHAMM isoforms in pancreatic tumor progression.
    Choi S; Wang D; Chen X; Tang LH; Verma A; Chen Z; Kim BJ; Selesner L; Robzyk K; Zhang G; Pang S; Han T; Chan CS; Fahey TJ; Elemento O; Du YN
    Mol Cancer; 2019 May; 18(1):92. PubMed ID: 31072393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular characterization of metastatic pancreatic neuroendocrine tumors (PNETs) using whole-genome and transcriptome sequencing.
    Wong HL; Yang KC; Shen Y; Zhao EY; Loree JM; Kennecke HF; Kalloger SE; Karasinska JM; Lim HJ; Mungall AJ; Feng X; Davies JM; Schrader K; Zhou C; Karsan A; Jones SJM; Laskin J; Marra MA; Schaeffer DF; Gorski SM; Renouf DJ
    Cold Spring Harb Mol Case Stud; 2018 Feb; 4(1):. PubMed ID: 29092957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression accurately distinguishes liver metastases of small bowel and pancreas neuroendocrine tumors.
    Sherman SK; Maxwell JE; Carr JC; Wang D; Bellizzi AM; Sue O'Dorisio M; O'Dorisio TM; Howe JR
    Clin Exp Metastasis; 2014 Dec; 31(8):935-44. PubMed ID: 25241033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences between Well-Differentiated Neuroendocrine Tumors and Ductal Adenocarcinomas of the Pancreas Assessed by Multi-Omics Profiling.
    Starzyńska T; Karczmarski J; Paziewska A; Kulecka M; Kuśnierz K; Żeber-Lubecka N; Ambrożkiewicz F; Mikula M; Kos-Kudła B; Ostrowski J
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32586046
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Satoh K; Sadowski SM; Dieckmann W; Quezado M; Nilubol N; Kebebew E; Patel D
    Ann Surg Oncol; 2016 Dec; 23(Suppl 5):714-721. PubMed ID: 27638678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.
    Marinoni I; Kurrer AS; Vassella E; Dettmer M; Rudolph T; Banz V; Hunger F; Pasquinelli S; Speel EJ; Perren A
    Gastroenterology; 2014 Feb; 146(2):453-60.e5. PubMed ID: 24148618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular alterations in sporadic pancreatic neuroendocrine microadenomas.
    Hadano A; Hirabayashi K; Yamada M; Kawanishi A; Takanashi Y; Kawaguchi Y; Nakagohri T; Nakamura N; Mine T
    Pancreatology; 2016; 16(3):411-5. PubMed ID: 26905832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of resection of the primary pancreatic neuroendocrine tumor in the multidisciplinary treatment of patients with unresectable synchronous liver metastases: a case series.
    Kondo NI; Ikeda Y; Maehara S; Sugimoto R; Nishiyama K; Sakaguchi Y
    JOP; 2013 Jul; 14(4):415-22. PubMed ID: 23846939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. UCHL1 loss alters the cell-cycle in metastatic pancreatic neuroendocrine tumors.
    Finnerty BM; Moore MD; Verma A; Aronova A; Huang S; Edwards DP; Chen Z; Seandel M; Scognamiglio T; Du YN; Elemento O; Zarnegar R; Min IM; Fahey TJ
    Endocr Relat Cancer; 2019 Apr; 26(4):411-423. PubMed ID: 30689542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis.
    Duerr EM; Mizukami Y; Ng A; Xavier RJ; Kikuchi H; Deshpande V; Warshaw AL; Glickman J; Kulke MH; Chung DC
    Endocr Relat Cancer; 2008 Mar; 15(1):243-56. PubMed ID: 18310291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CT texture analysis of liver metastases in PNETs versus NPNETs: Correlation with histopathological findings.
    Martini I; Polici M; Zerunian M; Panzuto F; Rinzivillo M; Landolfi F; Magi L; Caruso D; Eid M; Annibale B; Laghi A; Iannicelli E
    Eur J Radiol; 2020 Mar; 124():108812. PubMed ID: 31951893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Surgery for Pancreatic Neuroendocrine Tumors.
    Ziogas IA; Schmitz R; Moris D; Vatsaas CJ
    Anticancer Res; 2022 Feb; 42(2):629-639. PubMed ID: 35093860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of glucagon-like Peptide 1 receptor and its effects on biologic behavior in pancreatic neuroendocrine tumors.
    Cases AI; Ohtsuka T; Fujino M; Ideno N; Kozono S; Zhao M; Ohuchida K; Aishima S; Nomura M; Oda Y; Mizumoto K; Tanaka M
    Pancreas; 2014 Jan; 43(1):1-6. PubMed ID: 24326362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. α-Internexin: a novel biomarker for pancreatic neuroendocrine tumor aggressiveness.
    Liu B; Tang LH; Liu Z; Mei M; Yu R; Dhall D; Qiao XW; Zhang TP; Zhao YP; Liu TH; Xiao Y; Chen J; Xiang HD; Wu HY; Lu CM; Lv B; Zhou YR; Zhang Y; Deng D; Chen YJ
    J Clin Endocrinol Metab; 2014 May; 99(5):E786-95. PubMed ID: 24483152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulinoma-associated protein 1 (INSM1) is a robust marker for identifying and grading pancreatic neuroendocrine tumors.
    Kim D; Viswanathan K; Goyal A; Rao R
    Cancer Cytopathol; 2020 Apr; 128(4):269-277. PubMed ID: 31977134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.